Category - Developments

Developments

Imara gets EC orphan drug designation for sickle cell disease

Imara’s (NASDAQ:IMRA) IMR-687 received European Commission orphan drug designation for the treatment of sickle cell disease. In a statement, Imara’s president and CEO, Rahul Ballal, said the designation reinforces “the...

August 25, 2020

Developments

Bristol Myers Squibb to acquire TIAP’s Forbius

Bristol Myers Squibb (NYSE:BMY) entered a definitive agreement to acquire closely-held Forbius, a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and...

August 24, 2020

Developments

CohBar begins Phase 1b trial with CB4211 for NASH and obesity

CohBar (NASDAQ:CWBR) dosed first subjects with CB4211 in the Phase 1b stage of its Phase 1a/1b clinical trial for non-alcoholic steatohepatitis (NASH) and obesity. The Phase 1b study is designed to evaluate one dose...

August 24, 2020

Developments

Bionano Genomics acquires Lineagen to boost genetics diagnostics

Bionano Genomics (NASDAQ:BNGO) acquired closely-held Lineagen, a genetics diagnostic company, to further support its leadership in digital cytogenetics and comprehensive genetic diagnostics for pediatric...

August 24, 2020

Developments

Entera Bio reports interim data from Phase 2 osteoporosis trial

Entera Bio (NASDAQ:ENTX) reported interim results from its Phase 2 trial assessing EB613 for the treatment of osteoporosis. The trial has currently enrolled 131 postmenopausal female subjects with osteoporosis, or low...

August 20, 2020

Developments

Precision BioSciences gets FDA fast track designation for allogeneic CAR-T cell therapy

Precision BioSciences’ (NASDAQ:DTIL) allogeneic chimeric antigen receptor (CAR-T) cell therapy, PBCAR0191, received FDA fast track designation for the treatment of advanced B-cell precursor acute lymphoblastic leukemia...

August 20, 2020

Developments

Kazia gets FDA fast track designation for glioblastoma

Kazia Therapeutics’ (NASDAQ:KZIA) paxalisib received FDA fast track designation for the treatment of glioblastoma. Interim data from the company’s Phase 2 trial demonstrated overall survival of 17.7 months for patients...

August 20, 2020

Developments

IntelGenx in feasibility pact with ATAI for film-based psychedelics

IntelGenx (TSXV:IGX; OTCQB:IGXT) and ATAI Life Sciences signed a feasibility agreement for the development of novel formulations of pharmaceutical-grade psychedelics, based on IntelGenx’s film technologies. Under...

August 20, 2020

Developments

Albireo Pharma ends development of elobixibat for NASH/NAFLD

Albireo Pharma (NASDAQ:ALBO) reported topline results from its Phase 2 trial evaluating elobixibat for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). The trial...

August 18, 2020

Developments

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) reported interim results from its Phase 3 trial assessing tradipitant for the treatment of COVID-19 pneumonia. The data are based on the first 60 patients enrolled in the study, who...

August 18, 2020

Category - Developments

Imara gets EC orphan drug designation for sickle cell disease

Bristol Myers Squibb to acquire TIAP’s Forbius

CohBar begins Phase 1b trial with CB4211 for NASH and obesity

Bionano Genomics acquires Lineagen to boost genetics diagnostics

Entera Bio reports interim data from Phase 2 osteoporosis trial

Precision BioSciences gets FDA fast track designation for allogeneic CAR-T cell therapy

Kazia gets FDA fast track designation for glioblastoma

IntelGenx in feasibility pact with ATAI for film-based psychedelics

Albireo Pharma ends development of elobixibat for NASH/NAFLD

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

General

More